CRVS News and Press, Corvus Pharmaceuticals Inc. From 02/08/24

2024-02-08 17:13:43 ET Gainers: Farmer Brothers  ( FARM ) +15% . Corvus Pharmaceuticals  ( CRVS ) +10% . Impinj ( PI ) +9% . CalAmp ( CAMP ) +6% . Arbutus Biopharma Corporation ( ABUS ) +6% . Losers: Affirm Hold...

2024-02-08 16:58:54 ET More on Corvus Pharmaceuticals Corvus Pharmaceuticals: Ahead Of The Clinical-Stage Curve Seeking Alpha’s Quant Rating on Corvus Pharmaceuticals Historical earnings data for Corvus Pharmaceuticals Financial information for Corvus ...

BURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphom...

BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial...

BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. The Company extends its condolences...

2024-01-04 12:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting December 2023 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling...

2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...

2023-12-10 07:30:00 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: The Week Ahead

Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need for new treatments for peripheral T cell lymphoma (PTCL) Results confirmed patient eligib...

2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...